Event Type: Quarterly earnings conference call for analysts and investors following Q1 FY2027 results announcement
Date and Time: Wednesday, July 29, 2026, at 04:30 P.M. IST (Indian Standard Time)
Purpose: Discussion of the company's standalone and consolidated unaudited financial results for the quarter ended June 30, 2026 (Q1 FY2027)
Timing Relative to Earnings: The call is scheduled after the Board of Directors meeting to consider and approve the financial results, as referenced in the company's letter dated July 23, 2026
Management Participants: Not explicitly disclosed in this intimation
Presentation Availability: The company states that details of the call are "attached herewith and are also available on Company's website"
UPSI Compliance: The disclosure is made pursuant to Regulation 30 and other applicable regulations of the SEBI (LODR) Regulations, 2015, indicating regulatory compliance
Additional Notes Section
Attachments: The document mentions an enclosure ("Encl.: a/a") and specifically references attached details of the call
Financial Data Disclosure: No financial figures, guidance, or strategic updates are included in this announcement - it serves purely as an intimation of the scheduled call
Access Logistics: The call will be conducted via Zoom, with pre-registration required through a provided link: https://zoom.us/webinar/register/WN_AH5SYmDJSu6TzrMoYbS9pg
Investor Relations Contact: Atul Modi from Investor Relations is listed as the contact point with email atul.modi@eristherapeutics.com
RSVP: Participants are requested to RSVP through the company website: https://eris.co.in/
